Evolocumab - CISMeF

Preferred Label : Evolocumab;

NCIt definition : A human immunoglobulin G2 (IgG2) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia. Upon administration, evolocumab targets, binds to and inhibits the activity of PCSK9. This prevents binding of PCSK9 to low-density lipoprotein receptor (LDLR) on hepatocytes and prevents its degradation. This increases LDLR on hepatocytes and increases the liver's ability to remove LDL cholesterol (LDL-C) from the blood, thereby lowering LDL-C levels. PCSK9 binds to LDLR on the surface of hepatocytes to promote LDLR degradation within the liver.;

UNII : LKC0U3A8NJ;

CAS number : 1256937-27-5;

Drug name : Repatha;

Molecule name : AMG 145; AMG-145;

NCI Metathesaurus CUI : CL1412172;

Details

Origin ID

C174672;

UMLS CUI

C3529352;

CISMeF manual mappings
- evolocumab [MeSH Supplementary Concept]
- evolocumab [MeSH concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Evolocumab (substance) [SNOMED CT concept]
- Product containing evolocumab (medicinal product) [SNOMED CT concept]
- evolocumab [MeSH Supplementary Concept]
- evolocumab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients